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 18 
ABSTRACT 19 
A peptide-based indirect ELISA was developed to detect antibodies against Equine 20 
arteritis virus (EAV). Two peptides for epitope C of protein GP5 and fragment E of protein 21 
M were designed, synthesized, purified and used as antigens either alone or combined. 22 
Ninety-two serum samples obtained from the 2010 equine viral arteritis outbreak, analyzed 23 
previously by virus neutralization, were evaluated by the ELISA here developed. The best 24 
resolution was obtained using peptide GP5. The analysis of the inter- and intraplate 25 
variability showed that the assay was robust. The results allow concluding that this 26 
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peptide-based ELISA is a good alternative to the OIE-prescribed virus neutralization test 1 
because it can be standardized between laboratories, can serve as rapid screening, can 2 
improve the speed of diagnosis of EAV-negative horses and can be particularly useful for 3 
routine surveillance in large populations.  4 
KEY WORDS synthetic peptides- ELISA- Equine arteritis virus 5 
 6 
Equine arteritis virus (EAV) belongs to the order Nidovirales, family Arteriviridae, 7 
genus Arterivirus (Snijder and Meulenberg, 1998). The most relevant feature of EAV 8 
infection is that it produces subclinical infection. However, the most important clinical signs 9 
of the disease are abortions, respiratory disease in adult animals and pneumonia in foals. 10 
In Argentina, although serological evidence was first documented in 1984 (Nosetto et al., 11 
1984), EAV was first isolated in 2001 (Echeverría et al., 2003). Following the EAV 12 
outbreak in 2010, the number of samples sent to the laboratory for EAV analysis was 13 
significantly higher than the annual average of the previous years, reaching almost 5000 14 
samples analyzed over a period of seven months. This increase highlighted the need for 15 
an alternative technique to replace the virus neutralization test, which is, to date, the test 16 
for international trade prescribed by the OIE (OIE, 2012). The virus neutralization test 17 
detects antibodies against to EAV GP5 protein but is complex and high cost and requires 18 
72 h to yield a result. Other difficulties include the considerable interlaboratory variation 19 
and the contamination or nonspecific cellular cytotoxicity in sera from vaccinated horses 20 
(Newton et al., 2004). Although several ELISAs have been developed, none have been 21 
validated as extensively as the virus neutralization test. Some, however, offer comparable 22 
specificity and almost equivalent sensitivity. The aim of this work was to design an ELISA 23 
as a screening assay for EAV, using synthetic peptides. Indirect ELISA using peptides 24 
containing GP5 neutralization epitopes may provide a simpler and more cost-effective 25 
method to quantify EAV antibodies than the virus neutralization test. Another benefit of an 26 
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EAV ELISA is that it can provide a same-day test result compared with the 72 h needed for 1 
the virus neutralization test. 2 
 3 
The two peptides used were a fragment of the V1 region of the GP5 protein –4 
epitope C- (amino acids 67-90) – VFLDDQIITFGTGCNDTHSVPVST, and a fragment 5 
corresponding to the C terminal region of the M protein-Cterm -fragment E- (amino acids 6 
130-162) AVGNKLVDGVKTITSAGRLFSKRAAATAYKLQ. These peptides were designed 7 
according to the analysis of the Argentine LP02/C EAV strain (FIG. 1). The peptides were 8 
manually synthesized by solid phase peptide synthesis using the standard Fmoc (9-9 
fluorenylmethyloxycarbonyl) protocols on a RinkMBHA resin of 0.6 mmol/g. The crude 10 
peptides were purified by semi-preparative HPLC on a Beckman System Gold with a 11 
reverse-phase C18 column, resulting in purity greater than 95%, checked by analytical 12 
HPLC on a Shimadzu system. The identity of the peptide was confirmed by mass 13 
spectrometry in positive ion mode ESI on a Bruker model apparatus. The two peptides 14 
were used either separately or together as antigens in the development of the ELISA.  15 
 16 
Ninety-two horse serum samples from the 2010 EAV outbreak characterized 17 
previously by the virus neutralization test (46 positive and 46 negative) were obtained from 18 
the Laboratory of Virology of the School of Veterinarian Sciences of the University of La 19 
Plata (Buenos Aires, Argentina).  20 
 21 
The optimal dilutions of each coating peptide, serum sample and secondary 22 
antibody were determined by checkboard titration in microtiter plates (Maxisorp Nunc, 23 
Roskilde, Denmark). Peptides were diluted from 100 µg/ml (stock solution of 2000 µg/ml) 24 
to 0.0488 µg/ml. Positive and negative sera were tested at dilutions from 1:2 to 1:256. 25 
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Horseradish peroxidase-conjugated rabbit anti-horse antibody (Sigma Chemical, St. Louis, 1 
MO, USA) was used at a dilution of 1:2000.  2 
 3 
In a preliminary step, both peptides were evaluated either alone or in combination. 4 
Peptide GP5 showed better discrimination between positive and negative sera than 5 
peptide M or both (FIG. 2). Briefly, wells were coated with 100 μl of peptides dissolved in 6 
50 mM carbonate/bicarbonate buffer, pH 9.6 (Na2CO3 1.59 g, NaHCO3 2.93 g up to 1000 7 
ml H2O) at a concentration of 12 µg/well and incubated at 37ºC for 3 h and then at 4ºC 8 
overnight. After removing the excess of unbound antigen, 100 μl of blocking solution (PBS, 9 
0.05% bovine seroalbumin) was added to each well and the wells further incubated at 10 
37ºC for 30 min and then rinsed with PBS containing 0.05 % Tween 20 (PBS-T). A 50-µl 11 
volume of 1:8 dilutions of horse sera in blocking solution was added in duplicate and 12 
incubated at 37ºC for 1 h. After rinsing with PBS-T, the wells were incubated with 50 µl of 13 
horseradish peroxidase-conjugated rabbit anti-horse IgG (diluted 1:2000 in blocking 14 
solution) at 37ºC for 1 h. Finally, after three washings, a 100-μl volume of 1 mM 2,2’-azino-15 
bis (3-ethylbenzothiazoline-6-sulfonic acid) ABTS (Sigma Chemical) substrate solution 16 
was added to each well and the wells then incubated at room temperature for 20, 30 and 17 
60 min. The optical density (OD) was read at 405 nm using an automatic ELISA reader.  18 
The OD raw values were corrected according to the following formula: OD (sample)-19 
(background OD of sample)/ OD (positive control)-(background OD of positive control). To 20 
determine the cut-off value of the ELISA, the OD values were analyzed with Stata_SE 9.2 21 
software (Stata Corporation, TX, USA). In the first step, the values obtained were analyzed 22 
by Receiver Operating Characteristic (ROC) curves, where the true positive rate 23 
(sensitivity) is plotted as a function of the false positive rate (100-specificity) for different 24 
cut-off points. Each point on the ROC plot represents a sensitivity/specificity pair 25 
corresponding to a particular decision threshold. To evaluate intra-and inter-plate 26 
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repeatability, each serum sample was seeded in two wells of the same plate and then 1 
repeated on a new plate. The coefficients of variation (CVs) were calculated based on the 2 
raw values of OD between the wells of the same plate and between the wells of both 3 
plates.  4 
 5 
The optimal concentration of each peptide used was 12 μg / ml and the optimal 6 
dilution of equine sera (1:8) in this indirect ELISA was determined by checkboard titration 7 
to give the maximum discrimination between the reference positive and negative sera 8 
selected. The optimal reading was set to 30 min. The best results with minimum 9 
background were obtained using peptide GP5 alone (FIG. 2). A total of 92 equine serum 10 
samples from the outbreak of equine viral arteritis of 2010, characterized previously as 11 
EAV-positive or EAV-negative by virus neutralization, were assayed using this ELISA. The 12 
analysis of the graphic of ROC showed that the area under the curve was 0.94, with a high 13 
confidence interval (95% CI) of 90–99%. The cut-off value selected was 0.5, with a 14 
sensitivity of 95.65% and a specificity of 80.43%. This cut-off value allowed correctly 15 
classifying 88.04% of the serum samples as true positive or true negative (Table 1 and 16 
FIG. 3). 17 
 To determine intra- and inter-plate repeatability, none of the coefficients of variation 18 
calculated exceeded the value reported as correct (Jacobson, 1998). The summary is 19 
shown in Table 2. 20 
 21 
The objective of this study was to design an ELISA as screening of EAV by using 22 
synthetic peptides as antigens. Other peptide-based ELISAs have been shown to be 23 
sensitive and specific indirect diagnostic tools in virology, such as to discriminate between 24 
serological responses to equine herpesvirus 1 and 4 (Lang et al., 2013), foot and mouth 25 
disease (Gao et al., 2012; Oem et al., 2005), classical swine fever (Lin et al., 2010), 26 
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equine infectious anemia (Soutullo et al., 2001) and porcine reproductive and respiratory 1 
syndrome virus (Plagemann, 2006). To define the cut-off value of the ELISA, the 2 
prevalence of the 2010 equine viral arteritis outbreak (2%) and the correlation of the ELISA 3 
test results with the virus neutralization test as gold standard were considered. A cut-off 4 
value of 0.5 allowed reaching a high percentage of sensitivity and clearly distinguishing the 5 
negative sera. By definition, a screening test must be easy to use and inexpensive and 6 
should be highly sensitive, so that it fails only in a small number of infected animals 7 
(Pfeiffer, 2002). Any positive result should undergo confirmatory testing and thus reduced 8 
specificity should be tolerated. The ELISA developed in the present work allowed 9 
separating the negative samples in a shorter time than virus neutralization. 10 
The peptides designed in the present study represent the main neutralization site of 11 
GP5 and were strategically designed on the basis of the Argentine EAV sequences 12 
(Echeverría et al., 2010) to use this ELISA in infected horses of Argentina. Other authors 13 
have found that G16,  located between amino acids 79 to 94, is a high antigenic peptide. 14 
(Kondo et al., 1998). The peptides designed overlap in 12 out of 16 amino acids. Other 15 
ovoalbumin-conjugated synthetic peptide-based ELISAs designed with amino acids 81 to 16 
106 of GP5 of the EAV Bucyrus strain were used as diagnostic antigen. The sensitivity and 17 
specificity were 96.75% and 95.6% respectively (Nugent et al., 2000). In the ELISA 18 
developed in this work the sensitivity is almost the same. The strain variation and the 19 
region selected could be responsible of the difference of specificity. As horses in Argentina 20 
are infected with strains belonging to the European cluster (Metz et al., 2011) and 21 
vaccination is made with the American Bucyrus strain, it will be of interest to test whether 22 
this ELISA can distinguish EAV naturally infected horses from vaccinated ones. In this 23 
work, no positive sera from horses infected with the American strain were used. As 24 
suggested by Kondo et al. (1998), the reactivity to the peptide is highly specific to the 25 
homologous strain. These authors showed that a horse experimentally infected with a 26 
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heterologous strain (not American) does not react with the peptide by an ELISA designed 1 
over the Bucyrus strain. Other authors have been able to discriminate between serological 2 
responses to European-genotype vaccines and European-genotype field strains of porcine 3 
reproductive and respiratory syndrome virus, by using an ORF 4 peptide-based ELISA 4 
(Oleksiewicz et al., 2005). 5 
To determine the significance of amino acid composition in the anti-EAV response, 6 
it would be of interest to include a larger ectodomain of EAV strains with larger variation in 7 
amino acid sequence than the LP02/C strain. Although the linear antigenic region of GP5 8 
was identified and comprises amino acids 75 to 98, it is uncertain whether the antibody 9 
response against an attenuated or inactivated EAV vaccine could be determined using a 10 
peptide ELISA.  11 
ELISA procedures can be standardized between laboratories and could serve as 12 
rapid screening, thus improving the speed of diagnosis of EAV-negative horses and 13 
becoming useful for routine surveillance in large populations. Results of the present work 14 
show that the ELISA developed is a suitable alternative to the virus neutralization test for 15 
serodiagnosis of EAV in Argentina. 16 
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 1 
Figure legends 2 
 3 
Figure 1: Alignment of the amino acid sequences of the GP5 and M proteins of laboratory 4 
and field strains of Equine arteritis virus (EAV). Neutralization sites B, C and D (variable 5 
region V1) are indicated in the boxes. The amino acid sequences of the synthetic peptides 6 
synthesized were based on the LP02/C strain of EAV (boxes in bold).  7 
 8 
Figure 2: Reactivity of positive and negative EAV horse sera to synthetic peptides.  9 
 10 
Figure 3: Statistical analysis of peptide-ELISA results. (A) Receiver Operating 11 
Characteristic (ROC) analysis using STATA SE 9.2 st tistical analysis software (CI 95% 12 
0.90–0.99). (B) Report of sensitivity and specificity by STATA software. A cut-off value of 13 
0.5 classified serum samples correctly in the maximum value (88.04%), with highest 14 
sensitivity (95.65%) and good specificity (80.43%). 15 
 16 
17 
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 1 
Table 1: Results of antibody detection over 92 analyses using the virus neutralization test 2 
and peptide-ELISA developed in the present work (cut-off 0.5). 3 
 4 
 5 
 virus neutralization 
positive 
virus neutralization 
negative 
Total 
ELISA positive 44 9 53 
ELISA negative 2 37 39 
Total 46 46 92 
 6 
Sensitivity 95.65% 7 
Specificity 80.43% 8 
Positive predictive value 83.02% 9 
Negative predictive value 94.87% 10 
 Kappa (95% CI)= 0.760 (0.696-0.825) 11 
 12 
 13 
14 
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 1 
Table 2: Intra- and inter-plate precision of the peptide-ELISA 2 
 3 
Precision test Plate maximum CV (%) minimum CV (%) 
 
Intraplate repeatability 
 
Plate 1 
 
 
10.70 
 
0.21 
 Plate 2 13.72 0.00 
 Plate 3  15.59 0.00 
 Plate 4 19.85 0.00 
 
Interplate repeatability 
 
Plate 1 vs. plate 2
 
 
14.89 
 
1.44 
 Plate 3 vs. plate 4 13.20 0.87 
 4 
CV= coefficient of variation  5 
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